The Participation of Clay B. Siegall in the Pharmaceutical Industry

Clay B. Siegall is a revered science professional who has gained recognition in the pharmaceutical industry due to the significant steps that he has made towards the treatment of cancer. He co-founded Seattle Genetics, which is a top pharmaceutical corporation that has been operational since 1998. Siegall has been the CEO and president of the firm and has guided it making new scientific discoveries, drugs, and conducting extensive research. He has led Seattle Genetics and its scientists in the development of various therapies that can be helpful in the treatment of cancer. The company has currently developed very effective antibody-drug conjugates (ADCs) that are used in curing cancer. The first commercial ADC that it developed was ADCETRIS®, and it got the approval of the FDA in 2011. The drug has been successful, and it is allowed in over 65 countries across the globe. The international branding and distribution of ADCETRIS® have been facilitated by Seattle Genetics’ partnership with Takeda Pharmaceutical Company. Siegall has been motivating the researchers who work at his company to better the ADCs that it is already producing.

 

Dr. Siegall has ensured that the firm runs its global manufacturing and supplying services efficiently by obtaining all the required licenses. The main ADC drugs that the company currently sells are AbbVie, Pfizer, GlaxoSmithKline, and Genentech. Seattle Genetics has made about $350 million from selling the drugs across the globe. The unique technology that they corporation established has been used in the development of over 20 ADCs. Seattle Genetics has been manufacturing its drugs internally and also externally by partnering with other pharmaceutical companies across the globe. Clay Siegall has formed great financing strategies that the firm has used in securing over $1.2 billion from investors since 2001.

 

Clay had a successful profession in the pharmaceuticals industry before he joined Seattle Genetics. He entered the sector by working for National Cancer Institute where he served for a couple of years before being hired by the Bristol-Myers Squibb Pharmaceutical Research Institute. Washington Roundtable, Ultragenyx Pharmaceutical, and BioPharmaceutica trust his administration skills and have appointed him as a member of their boards.

 

Leave a Reply